anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND AIMS: Current evidence on the relationship between dietary carotenoids intake (DCI) and chronic kidney disease (CKD) are limited. Moreover, whether there is an association between DCI and prevalence of CKD and how this association might be impacted by sex is not clear.
METHODS AND RESULTS: Overall, 4507 women and 4396 men were included for analysis. The study used data from the National Health and Nutrition Examination Survey (NHANES), a cross-sectional survey carried out in the USA. The exposure factor for this analysis was DCI. The outcome was CKD, defined as eGFR < 60mL/min/1.73 m2. Multivariate logistic regression was used to analyzed the associations of DCI and prevalence of CKD both in men and women. There was a significant inverse association between higher DCI and prevalence of CKD only among females. Per LgDCI unit increment, the multivariable adjusted odd ratio (OR) (95% confidence interval) for prevalence of CKD was 0.72 (0.58, 0.90) in females and 0.95 (0.77, 1.18) in males. When compared with the lowest quartile, the ORs of the highest quartile of DCI for prevalence of CKD were 0.59 (0.40, 0.87) in females and 0.87 (0.60, 1.26) in males. The associations remained similar in the subgroup analyses.
CONCLUSIONS: The findings suggest that a higher intake of dietary carotenoids is associated with a lower prevalence of CKD in women, but not in men.
Patients and caregivers allocated to the Wawokiya Health Advocate arm will receive a palliative intervention consisting of regular needs assessments and home visits. After the first 2 visits, visits will occur bi-weekly, though a WHA may increase or decrease frequency of visits pending patient and caregiver needs and cancer status. The first two study visits will follow the same broad structure-structure of follow up visits will be flexible based on patient and caregiver needs. The location of study visits will vary and may include the local IHS site, cancer centers, and the patient's home depending on health status. Patients will be randomized to either receive home visits upon enrollment or be placed on a waitlist.
SIGNIFICANCE: Shuntodynia is patient reported pain at the site of the implanted ventriculoperitoneal (VP) shunt. Pediatric hydrocephalus requiring shunt placement is a chronic and prevalent standard of care treatment and requires lifetime management. Shuntodynia is a subjective measure of shunt dysfunction. Quantitative, white-light tissue spectroscopy could be used to objectively identify this condition in the clinic.
AIM: Pediatric subjects were recruited for optical sensing during routine clinical follow-up visits, post-VP shunt implantations. Acquired optical signals were translated into skin-hemodynamic signatures and were compared between subjects that reported shuntodynia versus those that did not.
APPROACH: Diffuse reflectance spectroscopy (DRS) measurements were collected between 450 and 700 nm using a single-channel fiber-optical probe from (N=35) patients. Multiple reflectance spectra were obtained by the attending physician from regions both proximal and distal to the VP shunt sites and from a matched contralateral site for each subject. Acquired reflectance spectra were processed quantitatively into functional tissue optical endpoints. A two-way, repeated measures analysis of variance was used to assess whether and which of the optical variables were statistically separable, across subjects with shuntodynia versus those without.
RESULTS: Analyses indicated that intrapatient differences in vascular oxygen saturation measured between shunt sites relative to that obtained at the scar or contralateral sites was significantly lower in the pain group. We also find that the total hemoglobin concentrations at the shunt site were lowest relative to the other sites for subjects reporting pain. These findings suggest that shuntodynia pain arises in the scalp tissue around the implanted shunts and may be caused due to hypoxia and inflammation.
CONCLUSIONS: Optically derived hemodynamic variables were statistically significantly different in subjects presenting with shuntodynia relative to those without. DRS could provide a viable mode in routine bedside monitoring of subjects with VP shunts for clinical management and assessment of shuntodynia.
The present invention is a process for making a plurality of drug delivery devices for ocular delivery. The plurality of drug delivery devices are made in part of poly(vinyl alcohol). During the manufacturing process the poly(vinyl alcohol) is cured. The poly(vinyl alcohol) may be in the form of separate pieces, a unitary sheet or may be incorporated into the drug delivery device at the time of curing. During the step of curing the humidity is controlled to ensure improved consistency during the curing process. The improved consistency results in inventories of drug delivery devices that have different cure times.
Intramedullary nailing (IMN), "Rod and Screws" A metal rod is placed inside your thigh bone and secured in place by metal screws just below the hip and above the knee. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary.
Post-stroke epilepsy may occur after aneurysmal subarachnoid hemorrhage (aSAH). Both early and late seizures could cause severe neurocognitive deficits if administration of appropriate antiseizure medication is delayed. Therefore, it is important to elucidate the risk factors for early and late seizures, which could be shared with medical teams to promptly manage seizures. There are aspects of both hemorrhage and ischemia in aSAH, and thus, numerous risk factors are considered for early and late seizures. We examined factors associated with aSAH-related early and late seizures. Among 297 patients who had aSAH and underwent direct or endovascular surgery, 25 had early seizures and 20 had late seizures. Patients who did not experience any seizures in at least 2-years of follow-up (n = 81) were used as the control group. Early seizures were associated with older age and acute severe nonneurological infection, whereas late seizures were associated with intraparenchymal lesion volume >10 mL and shunt placement. In patients with late seizures, consistency was frequently observed between electroencephalogram and the presence of intraparenchymal lesions. The frontopolar electrode on electroencephalogram was highly sensitive to abnormality in early seizures. Early seizures were induced by the patient's systemic factors, which may lower the threshold for cortical excitability. Patients with intraparenchymal lesions who undergo shunt placement should be carefully followed up for late seizures.
This is a study in male Veterans 45-70 years of age who meet the modified Kansas and Centers for Disease Control and Prevention (CDC) criteria for GWI (Gulf War Illness) and have high physiologic stress. This phase I single-site, open-label, two-arm study will focus on optimizing the dosage of a sequential etanercept-mifepristone intervention for GWI. Twenty participants will be assessed at baseline, 6, 12, 13, 16 and 24 weeks. The investigators will use systems biology methods to perform computational modelling of physiological responses to supervised maximal exercise challenge studies on a fitness bicycle at baseline and 24 weeks. These analyses will assess the impact of the treatment on homeostatic networks: the changes in levels of physiological parameters and the changes in inter-correlations among the measured parameters (e.g., cytokines), cross-sectionally and over time. Participants will also undergo subjective assessments of functional health, symptom severity, pain, fatigue, and cognition at baseline, 6, 12, 13, 16, and 24 weeks. Participants will be observed through the treatment period and for 3 months after completion to assess immediate effects and durability of the response.

The results of this phase I study will be compared to those from an existing short-duration study to identify the optimal duration and dosage for use in a future phase II study.
Patients will receive questionnaires to establish their attitudes/beliefs toward hypnosis, baseline pain, anxiety, \& shoulder function. 7 days before surgery, they will receive a pre-recorded video (\~19 min) of guided hypnosis to be watched at least 1x/day, until surgery. Before \& after the video, they will rate pain/anxiety levels. On the day of surgery, they will watch the video again \& answer questions about their average anxiety and pain level. After surgery, they will watch the video each day and report on pain/anxiety, medication use, satisfaction, and sleep disturbance until postoperative day 7. Postoperative course will be otherwise completely standard of care, including a clinic visit at 10 days after surgery, where they will be given these same questionnaires. Patients will answer them again on postoperative day 49, constituting a study endpoint. Access to pain medication \& study doctor will be the same as any shoulder arthroplasty patient regardless of study participation.
The invention discloses an umbilical therapy formula for treating cold dysmenorrhoea and a preparation method thereof. The composite material consists of the following raw materials in parts by weight: 30 parts of longan pulp, 20 parts of evodia rutaecarpa, 20 parts of cassia twig, 20 parts of peach seed and 10 parts of szechuan lovage rhizome. The preparation method of the formula comprises the following steps: cleaning and soaking longan pulp, and polishing to obtain slurry; then placing the slurry into an iron pan, and stir-frying until syrup appears; grinding the four materials into powder, adding into longan syrup, and stirring to obtain paste; compared with the prior art, the invention has the following beneficial effects: 1. the navel is the shenque acupoint in traditional Chinese medicine, the navel skin is the thinnest, the epidermis cutin is the thinnest, and the medicine is easy to penetrate. Meanwhile, the external medicine is easy to absorb and rapidly enters the blood circulation, thereby achieving the purpose of treatment. 3. The umbilical administration can reduce the irritation of the medicine to gastrointestinal tract and reduce the influence of the medicine to liver and kidney functions.
PURPOSE:To efficiently obtain the subject intermediate for the mycalamide excellent in the antiviral activity and anticancer activity by reacting a specific compound as a starting raw material under specified conditions. CONSTITUTION:A compound of formula I is reacted with a thiol in the presence of a Lewis acid and then reacted with acetone, etc., in the presence of an acid catalyst, and the produced compound is treated with a reducing agent and subsequently reacted with methyl orthoformate and an acid. The obtained compound is treated with a thioacetal-removing agent and then with a base to obtain a compound of formula II, which is treated with a reducing agent and subsequently treated with a methylating agent. The obtained compound is reacted with a peracid, hydrolyzed and treated with an acetylating agent, and the obtained compound is reacted with a propargyltrimethylsilane in the presence of a Lewis acid to produce a compound of formula III. The compound is hydrolyzed and then treated with a carbonylating agent, and the produced compound is oxidized with ozone and then reacted with paraformaldehyde and an acid. The obtained compound is treated with an acetylating agent and reacted with trimethylsilyl acid to provide the objective compound of formula IV.
The objective of this study was to investigate how Brazilian physical therapists (PTs) use therapeutic exercises in the rehabilitation of individuals with rotator cuff (RC) tendinopathy. The study used an online survey with a mix of 62 open- and closed-ended questions divided into three sections: participant demographics, professional experience, and clinical practice in the rehabilitation of patients with RC tendinopathy. One hundred and fifty-nine Brazilian physical therapists completed the survey. Most of our sample recommended isometric exercises (69.9%) in the initial phase of rehabilitation and eccentric exercises (47.4%) in the advanced phase. However, there was a wide variability in determining the volume of exercises, particularly with isometric exercises. Most of our sample considered patient comfort and pain levels when adjusting exercise intensity, regardless of exercise type. The majority (48.40%) recommended weekly reassessment and modification of exercises. Additionally, despite pain being a key factor for discharge and the primary adverse effect of exercise, most of our sample would not discontinue exercises in case of pain during the early and late phases of rehabilitation. Despite the lack of consensus on some aspects, the clinical practice of our sample is in line with the current literature and practice in other countries. However, further research and implementation are crucial to enhance future rehabilitation outcomes, including exploring the exercise training volume, the safety and effectiveness of exercising with pain and identifying the optimal pain level for best results.
Patients receive azacitidine IV or SC as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Bipolar Disorder (BPD), also known as manic-depressive illness, is a disorder that causes frequent shifts in an individual's mood, energy, and ability to function. An individual with BPD may go through periods of mania, which are characterized by increased energy, irritability, and an excessively "high" euphoric mood. The manic periods are followed by periods of depression, which are characterized by decreased energy, feelings of hopelessness, and anxiety. Rapid cycling bipolar disorder (RCBPD) is a type of BPD in which the individual experiences four or more episodes of mania and depression per year. The rapid shift between the manic and depressive episodes makes it imperative that individuals with RCBPD strictly manage their illness with medication. Many BPD medications have been developed recently; however, there are still many individuals who do not respond well to medication treatment. Research has shown that the way individuals experience illness has an effect on their response to medication. The purpose of this study is to gain insight into how individuals with RCBPD perceive and respond to medication treatment. Factors such as gender, degree of social support, drug and alcohol usage, and attitudes towards medication will be evaluated to understand how they affect medication and treatment adherence.

This study will consist of 1 visit, which will last approximately 2 and ½ hours and will include an anthropological interview and numerous standardized psychological questionnaires. The interview and questionnaires will assess participants' attitudes toward BPD treatment; psychiatric illness severity, including symptoms of mania and depression; expectations regarding recovery, stigma, and quality of life; and medication adherence.
Patients receive azacitidine SC or IV over 30-60 minutes on days 1-7, venetoclax PO QD on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles, and gilteritinib PO QD on days 1-28. Treatment of azacytidine and venetoclax repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Cycles of gilteritinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
YF476 is clearly a potent and selective gastrin/CCK-B antagonist and should inhibit basal and meal-stimulated gastric acid secretion and enhance gastric emptying of a liquid meal in man. Therefore YF476 might benefit patients with reflux oesophagitis. The compound has been remarkably well tolerated in animal toxicity studies at doses well in excess of the projected therapeutic dose in patients, and merits first administration to healthy volunteers. That study using the oral route of administration is described here. Extrapolation from data obtained with pentagastrin in animals suggest that single doses of less than 1mg of YF476 should be active in man. However, extrapolation from data obtained in comparative studies with the H2-antagonists and with omeprazole in animals suggest that the therapeutic dose in patients with reflux oesophagitis will be larger, in the region of 10mg. A range of single doses will be used in this study. The maximum dose will be 10 times more than the expected therapeutic dose.
Healthy participant who is receiving routine medical care (e.g., screening mammograms. Healthy participants are frequency-matched by age (± 2 years) and ethnicity.
A pharmaceutical composition having muscle relaxant activity in a form suitable for oral administration, e.g. tablet, powder or capsule, comprises at least 10 mg. of dicyclopropyl ketoxime and a solid non-toxic pharmaceutical carrier.  The carrier may form the container for the dicyclopropyl ketoxime as in the case of gelatin in a gelatin capsule.  The solid composition may contain binding agents, diluents and tabletting adjuvants, e.g. corn starch, acacia, lactose, talc, stearic acid, magnesium stearate and gums. The pharmaceutical composition may take the form of a liquid comprising an aqueous liquid pharmaceutical carrier containing at least 2 mg. of dicyclopropyl ketoxime per c.c. with a minimum of 10 mg. of dicyclopropyl ketoxime and a preservative and/or flavouring agent or agents, and/or one or more non-toxic suspending agents, e.g. acacia, carboxymethylcellulose, sodium carboxymethylcellulose, sucrose, glucose, glycerin, and esters of p-hydroxybenzoic acid.  The liquid composition may comprise a sterile aqueous liquid pharmaceutical carrier and be suitable for injection.
PROBLEM TO BE SOLVED: To optimize materials such as antibodies or antigens, etc., to be used in immunoassay, by performing an immune sensitization with a specific peptide or peptide derivative. SOLUTION: This provides an antigen and an antibody to a substance decomposed and produced from a type I collagen in humor, which specifically recognize the type I collagen or an amino acid sequence of Va-Gly-Leu-Gly in frequents of the type I collagen. The amino acid sequence is recognized in the collagen decomposed substance included in humor. In order to produce the antibody, animals are sensitized with a synthetic peptide or peptide derivative including an amino acid sequence corresponding to a sequence number 1 or a partial sequence including at least an amino acid sequence Val-Gly-Leu- Gly. The synthetic peptide preferably includes 6 or more amino acids. An amino acid bonded to the sequence Val-Gly-Leu-Gly is preferably bonded to an N terminal or C terminal of the sequence.
NEW MATERIAL:The compound of formula I (R1 is 16-18C straight-chain alkyl; the group of formula II is 5-6-membered ring residue having quaternarized N and optionally containing O) and its salt. EXAMPLE:1-0-Hexadecyl-2-0-acetyl-sn-glycero-3-( 2-N-methylpiperidioethyl )phosphate of formula III. USE:It has hypotensive and blood platelet coagulating activities, and is useful as a drug or its intermediate. PREPARATION:The compound of formula IV [e.g. 1-0-hexadecyl-sn-glycero-3-(2- N-methylpiperidioethyl)phosphate of formula V, etc.] is acetylated by reacting with e.g. acetyl anhydride preferably in an organic solvent in the presence of a base such as pyridine preferably under mild heating for 30min-several hours.
The recommended starting dose of Isosorbide Mononitrate Extended-Release Tablets is 30 mg (given as a single 30 mg tablet or as 1/2 of a 60 mg tablet) or 60 mg (given as a single tablet) once daily. After several days, the dosage may be increased to 120 mg (given as a single 120 mg tablet or as two 60 mg tablets) once daily. Rarely, 240 mg may be required.   
The daily dose of Isosorbide Mononitrate Extended-Release Tablets should be taken in the morning on arising. Isosorbide Mononitrate Extended-Release Tablets should not be chewed or crushed and should be swallowed together with a half-glassful of fluid. Do not break the 30 mg tablet.
Alprazolam XR contains alprazolam which is a triazolo analog of the 1,4 benzodiazepine class of central nervous system-active compounds.

The chemical name of alprazolam is 8-chloro-1-methyl-6-phenyl-4H-s-triazolo [4,3-α] [1,4] benzodiazepine. The molecular formula is C17H13ClN4 which corresponds to a molecular weight of 308.76.

The structural formula is represented below:

Alprazolam is a white crystalline powder, which is soluble in methanol or ethanol but which has no appreciable solubility in water at physiological pH.

Each Alprazolam XR extended-release tablet, for oral administration, contains 0.5 mg, 1 mg, 2 mg, or 3 mg of alprazolam. The inactive ingredients are colloidal silicon dioxide, hypromellose, lactose, and magnesium stearate. In addition, the 1 mg and 3 mg tablets contain D & C yellow No. 10 and the 2 mg and 3 mg tablets contain FD&C blue No. 2.
Triple antithrombotic therapy (TAT) regimen of aspirin 100mg q.d., clopidogrel 75mg q.d. plus warfarin (INR 1.8-2.5).
In a double blind multicenter, parallel group study, Enoxaparin Sodium Injection 20 mg or 40 mg once a day subcutaneously was compared to placebo in the prophylaxis of deep vein thrombosis (DVT) in medical patients with severely restricted mobility during acute illness (defined as walking distance of <10 meters for 3 days). This study included patients with heart failure (NYHA Class III or IV); acute respiratory failure or complicated chronic respiratory insufficiency (not requiring ventilatory support): acute infection (excluding septic shock); or acute rheumatic disorder (acute lumbar or sciatic pain, vertebral compression [due to osteoporosis or tumor], acute arthritic episodes of the lower extremities). A total of 1102 patients were enrolled in the study, and 1073 patients were treated. Patients ranged in age from 40 to 97 years (mean age 73 years) with equal proportions of men and women. Treatment continued for a maximum of 14 days (median duration 7 days). When given at a dose of 40 mg once a day subcutaneously, Enoxaparin Sodium Injection significantly reduced  
the incidence of DVT as compared to placebo. The efficacy data are provided below (see Table 20).

At approximately 3 months following enrollment, the incidence of venous thromboembolism remained lower in the Enoxaparin Sodium Injection 40 mg treatment group versus the placebo treatment group.
* Follow your doctor"s advice about how to take cilostazol. 
  * You should take cilostazol twice a day, at least one half-hour before or two hours after breakfast and dinner. Take cilostazol at about the same times each day. 
  * Do not share cilostazol with anyone else. It was prescribed only for you. 
  * Keep cilostazol and all drugs out of the reach of children.